J&J Heralds Year Of 'Good Momentum' For Consumer Health Business
This article was originally published in The Tan Sheet
Executive Summary
J&J says following a year of innovation, 2016 will be a year of growth for its consumer business on the return of more recalled OTC brands and strong positioning in consumers' emerging self-care trend. The firm reports consumer division sales in 2015 slipped 6.8%, with a 9.5% drag from foreign currency exchange.
You may also be interested in...
Medtech's High-Earners: 2016 Executive Payouts Boosted By Bonuses, Stock Awards
A Medtech Insight analysis of the highest-earning CEOs among the top medtech companies in last year's MTI 100 company league table shows that these individuals benefited mainly from stock and options holdings, as well as very generous incentive bonuses, bestowed upon them by their boards of directors. However, a couple of CEOs, including Zimmer Biomet's David Dvorak and Cardinal Health's George Barrett, who were rewarded fiscally for taking their companies to growth have had their leadership challenged since then.
J&J Consumer Products Business Steers Toward Acquisitions For Growth
Sales of Tylenol, Motrin and other analgesics increased more than 13% during the firm's latest quarter as total US OTC sales reached $389m. Sales of the Listerine line grew 7% to drive domestic oral care product sales up 8.2% to $159m.
J&J Consumer Products Business Steers Toward Acquisitions For Growth
Sales of Tylenol, Motrin and other analgesics increased more than 13% during the firm's latest quarter as total US OTC sales reached $389m. Sales of the Listerine line grew 7% to drive domestic oral care product sales up 8.2% to $159m.